title: Pulmonary edema induced by angiotensin I in rats.
abstract: This study was performed to demonstrate an experimental procedure of pulmonary edema induced by angiotensin I (AT I) in rats and to elucidate the mechanism of hemodynamic pulmonary edema. In the previous pilot study, 20 microg/kg of AT I was found to be an adequate dose for inducing pulmonary edema. To elucidate the mechanism of AT I pulmonary edema and protective measures against it, we observed the effects of captopril (CAP, 5 and 10 mg/kg), an angiotensin converting enzyme inhibitor; losartan (LOS, 10 mg/kg), an angiotensin II (AT II)-receptor antagonist; and phentolamine (PHE, 10 mg/kg), an alpha-adrenergic receptor blocker, on AT I-induced pulmonary edema in rats. Similarly, we also observed the effects of CAP (10 and 20 mg/kg) on pulmonary edema induced by 25 microg/kg of adrenaline (ADR) in rats. The development of AT I-induced pulmonary edema was significantly suppressed by CAP and LOS, but was unaffected by PHE. In contrast, the development of ADR-induced pulmonary edema was not suppressed by CAP. These results suggest that AT I-induced pulmonary edema is developed via the AT II and a specific AT II-receptor, without the indirect action of adrenaline.
authors.affiliation: Department of Preventive Medicine, Medical Research Institute, Tokyo Medical and Dental University, Japan.
authors.forename: Z H
authors.initials: ZH
authors.lastname: Xu
authors.forename: K
authors.initials: K
authors.lastname: Shimakura
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: L M
authors.initials: LM
authors.lastname: Wang
authors.forename: S
authors.initials: S
authors.lastname: Mineshita
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000803:Angiotensin I; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001794:Blood Pressure; D002216:Captopril / Q000494:pharmacology; D004837:Epinephrine; D019808:Losartan / Q000494:pharmacology; D005996:Nitroglycerin / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D011654:Pulmonary Edema / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control; D051381:Rats; D017208:Rats, Wistar; D011945:Receptors, Angiotensin / Q000187:drug effects / Q000378:metabolism; D012044:Regression Analysis; D012119:Respiration; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D000317:Adrenergic alpha-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D011945:Receptors, Angiotensin; D014665:Vasodilator Agents; D000803:Angiotensin I; D002216:Captopril; D005996:Nitroglycerin; D019808:Losartan; D004837:Epinephrine; D010646:Phentolamine